大剂量阿托伐他汀对不稳定性心绞痛患者冠脉狭窄程度hs-CRP的影响

doi:10.3969/j.issn.1006-6233.2017.06.07

Abstract
Figure/Table
References
Related Citation (5)

Download: PDF (1332 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the influence of high-dose atorvastatin on the degree of coronary artery stenosis, hs-CRP for unstable angina (UA) patients. Methods: 145 cases of UA patients admitted in our hospital from July 2013 to July 2015 were choosen as the research object, and those patients were randomly divided into two groups by the random number table method: the control group and study group. Both groups were given aspirin, metoprolol, and isosorbide dinitrate tablets as the conventional treatment. In the meantime, the control group (70 cases) was given Atorvastatin 10mg per day; while the study group (75 cases) was given atorvastatin 40mg per day. Before and after treatment of 7d, 15d, 30d treatment, high sensitivity C reactive protein in the patients of the two groups (hs-CRP) and a-lipoprotein level were recorded. And the pearson correlation analysis on the relationship between hs-CRP and the degree of coronary artery stenosis were analyzed. Results: The hs-CRP level of the study group were all significantly lower than that of the control group after 7-day and 15-day's treatment (P<0.05); the vascular embolization rate of the study group was significantly lower than that of the control group after 15-day and 30-day's treatment (P<0.05). And Pearson correlation analysis revealed that the serum hs-CRP were all significantly associated with the degree of coronary artery stenosis (r=0.264, P=0.032; r=0.425, P=0.014). Conclusion: Early large-dose application of atorvastatin can significantly reduce the level of hs-CRP and vascular embolization rate for UA patients, and the level of hs-CRP are positively correlated with the degree of coronary artery stenosis.

Key words： Atorvastatin Unstable angina hs-CRP

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LU Qingyu
	CHANG Yufeng
	LIU Geng

Cite this article:

LU Qingyu,CHANG Yufeng,LIU Geng. High Dose Atorvastatin on Coronary Artery Stenosis and hs-CRP in Patients with Unstable Angina Pectoris[J]. 河北医学, 2017, 23(6): 902-904.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2017.06.07 OR http://www.hbyxzzs.cn/EN/Y2017/V23/I6/902

[1] 中华医学会心血管病学会,中华心血管病杂志编辑委员.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295~304.
[2] Libby P. Current concepts of the pathogenesis of the acute coronary syndromes[J].Circulation, 2001, 104:365~372.
[3] 霍勇,葛均波,韩雅玲,等.急性冠状动脉综合征患者强化他汀治疗专家共识[J].中国介入心脏病学杂志,2014,22(1):4~6.
[4] 张卫萍,马云龙,马琼,等.血清脂蛋白相关磷脂酶A2与不稳定心绞痛患者主要危险因素的相关性[J].山西医科大学学报,2016年47(8):685~688.
[5] 杨功焕.中国人群死亡及其危险因素、流行水平、趋势和分布[M].北京:中国协和医科大学出版社,2005.111~113.
[6] 韩永继,盛小刚.不稳定型心绞痛治疗现状[J].中医杂志,2007,48(10):945~948.
[7] 郭新胜,施海明,罗心平,候旭敏.不同剂量阿司匹林对冠心病患者血小板聚集功能的影响[J].现代诊断与治疗,2002,13(2):105~106.
[8] 杨琴.血浆脂蛋白相关磷脂酶A2检测在冠状动脉粥样硬化中的应用价值[J].西部医学,2013,25(5):784~785,788.
[9] Rubinstein A, Izkhakov E.Lipoprotein associated phospholipase A2[J].Harefuah,2011,150(2):136~140,205.
[10] Zalewski A, Macphee C, Nelson JJ.Lipoprotein-associated phospholipase A2: a potential therapeutic target for atherosclerosis[J].Curr Drug Targets Cardiovasc Haematol Disord,2005,5(6):527~532.
[11] Tellis CC, Tselepis AD.The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma[J].Biochim Biophys Acta,2009,1791(5):327~338.
[12] Wilensky RL, Macphee CH.Lipoprotein-associated phospholipase A(2) and atherosclerosis[J].Curr Opin Lipidol,2009,20(5):415~420.
[13] 梁莉,钱娇玲,薛鸿燕,等.阿托伐他汀治疗不稳定型心绞痛的meta分析[J].中国药理学通报,2012,28(11):1500~1507.
[14] 孙丽君.不同剂量阿托伐他汀对冠状动脉狭窄程度的影响[J].中国保健营养(上旬刊) , 2013,23(9): 5195~5196.